U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07227922) titled 'Clofutriben Pharmacokinetics in Patients With Impaired Renal Function' on Nov. 06.
Brief Summary: This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Moderate Renal Impairment
Intervention:
DRUG: 12mg clofutriben
Each participant will receive a single oral dose of clofutriben
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sparrow Pharmaceuticals
Published by HT Digital Content Services with permission from...